Vanguard Group Inc. Grows Stake in Veeva Systems Inc. $VEEV

Vanguard Group Inc. lifted its holdings in shares of Veeva Systems Inc. (NYSE:VEEV) by 1.4% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 14,971,425 shares of the technology company’s stock after acquiring an additional 210,859 shares during the period. Vanguard Group Inc. owned 9.16% of Veeva Systems worth $4,311,471,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Alliancebernstein L.P. increased its stake in Veeva Systems by 10.7% in the first quarter. Alliancebernstein L.P. now owns 5,499,651 shares of the technology company’s stock valued at $1,273,884,000 after purchasing an additional 532,269 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its holdings in shares of Veeva Systems by 0.7% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 5,203,867 shares of the technology company’s stock valued at $1,205,372,000 after buying an additional 34,169 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Veeva Systems by 20.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,992,372 shares of the technology company’s stock valued at $924,754,000 after buying an additional 689,700 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Veeva Systems by 7.5% in the 1st quarter. JPMorgan Chase & Co. now owns 3,230,758 shares of the technology company’s stock valued at $748,341,000 after buying an additional 225,125 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in Veeva Systems by 3.8% during the 2nd quarter. Geode Capital Management LLC now owns 3,092,539 shares of the technology company’s stock worth $888,108,000 after acquiring an additional 114,003 shares in the last quarter. Hedge funds and other institutional investors own 88.20% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on VEEV shares. Raymond James Financial restated an “outperform” rating and issued a $340.00 price objective (up previously from $310.00) on shares of Veeva Systems in a research note on Thursday, August 28th. TD Cowen upgraded Veeva Systems from a “hold” rating to a “buy” rating and lifted their target price for the stock from $297.00 to $380.00 in a research report on Tuesday, October 7th. UBS Group upped their target price on Veeva Systems from $285.00 to $310.00 and gave the company a “neutral” rating in a research report on Thursday, August 28th. Evercore ISI lifted their price target on Veeva Systems from $285.00 to $295.00 and gave the stock an “in-line” rating in a research report on Thursday, August 28th. Finally, Wall Street Zen cut Veeva Systems from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Seventeen analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $307.28.

Insider Buying and Selling

In related news, SVP Jonathan Faddis sold 720 shares of Veeva Systems stock in a transaction on Monday, October 6th. The shares were sold at an average price of $298.12, for a total value of $214,646.40. Following the transaction, the senior vice president directly owned 7,868 shares in the company, valued at $2,345,608.16. This trade represents a 8.38% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Thomas D. Schwenger sold 3,350 shares of the business’s stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $300.04, for a total transaction of $1,005,134.00. Following the completion of the transaction, the insider directly owned 23,773 shares in the company, valued at $7,132,850.92. This represents a 12.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 24,665 shares of company stock valued at $7,438,000 over the last three months. 10.30% of the stock is currently owned by company insiders.

Veeva Systems Stock Down 0.2%

Shares of VEEV stock opened at $273.21 on Thursday. The stock’s 50-day moving average price is $288.57 and its 200 day moving average price is $278.53. The stock has a market capitalization of $44.78 billion, a PE ratio of 56.10, a price-to-earnings-growth ratio of 2.22 and a beta of 0.98. Veeva Systems Inc. has a 52-week low of $201.54 and a 52-week high of $310.50.

Veeva Systems (NYSE:VEEV) last posted its quarterly earnings data on Wednesday, August 27th. The technology company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.90 by ($0.64). Veeva Systems had a return on equity of 13.72% and a net margin of 27.29%.The company had revenue of $789.08 million for the quarter, compared to analyst estimates of $768.49 million. During the same period in the previous year, the business posted $1.62 earnings per share. The firm’s revenue was up 16.7% compared to the same quarter last year. Veeva Systems has set its Q3 2026 guidance at 1.940-1.950 EPS. FY 2026 guidance at 7.780-7.780 EPS. Analysts expect that Veeva Systems Inc. will post 4.35 earnings per share for the current fiscal year.

Veeva Systems Company Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.